ProteoGenix ads

40+ parameters scored before a candidate goes into production. Affinity is one of them, and rarely the one that kills a program. A sequence that binds in silico but fails to express, aggregates at concentration, or carries a chemical liability costs a full production cycle to find out. Those weeks get paid whether the candidate survives or not, and each one pushes the program’s timeline and budget out again. Scoring stability, developability, immunogenicity, solubility and chemical liabilities at the design stage moves that failure from the bench to the screen, where it costs compute, not calendar. Reviewed by our bioinformaticians. Corrected every cycle by ELISA and SPR/BLI data.

No binding sequence, no fee. Full IP ownership, no royalties. De novo AI antibody design — the risk sits on our side.

No binding sequence, no fee. Full IP ownership, no royalties. De novo AI antibody design — the risk sits on our side.

Transform your discovery timelines with AIxplore® de novo antibody design. You send a target sequence or 3D structure; in just 2–3 days you receive ranked sequences, and in 3 weeks up to 46 wet‑lab validated candidates. You only pay if at least one antibody binds (ELISA/FACS) and reaches ≥50 mg/L in CHO. Start removing biological bottlenecks today.

Go from a target structure to up to 46 antibody candidates produced, purified, and ranked by measured affinity in 3 weeks. De novo AI design removes immunization campaigns and library screening to deliver sequences with measured BLI or SPR data directly.

If traditional screening gave you few or no usable hits, AIxplore® offers a new route. You share the target sequence or structure; we explore alternative sequence and structural spaces with AI, then validate the best candidates by ELISA and BLI. With our no win, no fee model and guaranteed binding/CHO yield criteria, you can confidently reboot stalled projects.